Injecting drug users and HCV infection: prevention strategies and results

Damien Lucidarme M.D.
Hôpital saint Philibert,
Lomme, France
Introduction

- Intravenous drug use has become the principal route of HCV transmission
- Prevalence reported from Europe, the USA and Australia are usually high: 50% -> 90%
Prevalence of HCV markers according to the duration of IV drug use in 1991 in Lille

Contamination by HCV was almost inevitable after 2 years of intravenous drug use

Lucidarme et al. Gastroenterol Clin Biol 1994
Introduction

In order to prevent HIV and HCV transmission among IDUs, in 1993 the French health authorities implemented a national risk-reduction program based on:

1) easy access to syringes,
2) opiate substitution,
3) screening for HIV and HCV and counselling
1) easy access to syringes:
Evolution of the number of organizations and of funding dedicated to the risk-reduction policy

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Syringe-exchange-programmes</td>
<td>86</td>
<td>88</td>
<td>100</td>
<td>102</td>
<td>106</td>
</tr>
<tr>
<td>Storefronts</td>
<td>32</td>
<td>32</td>
<td>34</td>
<td>36</td>
<td>42</td>
</tr>
<tr>
<td>Automated devices</td>
<td>150</td>
<td>200</td>
<td>220</td>
<td>250</td>
<td>272</td>
</tr>
<tr>
<td>Total number</td>
<td>268</td>
<td>320</td>
<td>354</td>
<td>388</td>
<td>420</td>
</tr>
<tr>
<td>Funds</td>
<td>66 MF</td>
<td>79 MF</td>
<td>86 MF</td>
<td>92 MF</td>
<td>94 MF</td>
</tr>
</tbody>
</table>

Labrosse-Solier N. Journée nationale de l’échange des seringues en pharmacie. Lyon 2001
2) opiate substitution

Accessibility of IVDUs to substitution treatment from 1995 to 2003 (Siamois, InVS)

- Average number of monthly users of Méthadone
- Average number of monthly users of Subutex
3) screening for HIV and HCV

Frequency of recent detection (past 20 months) of hepatitis C according to age among the users of low-threshold organizations

<table>
<thead>
<tr>
<th>Age</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-24 years</td>
<td>37 %</td>
<td>33 %</td>
<td>49 %</td>
</tr>
<tr>
<td>25-35 years</td>
<td>50 %</td>
<td>53 %</td>
<td>66 %</td>
</tr>
<tr>
<td>&gt; 35 years</td>
<td>48 %</td>
<td>58 %</td>
<td>72 %</td>
</tr>
<tr>
<td>Total</td>
<td>46 %</td>
<td>50 %</td>
<td>63 %</td>
</tr>
</tbody>
</table>

Conférence de Consensus : Place des traitements de substitution. Lyon 2004
Does this policy work?
Evolution of access to substitution treatment and of deaths by overdose from 1995 to 2003 (Siamois, InVS)

Dr. J. Emmanuelli / InVS
Progress of access to substitution treatment and sterile syringes from 1995 to 2003 (Siamois, InVS)

Syringes:
- 20,000,000
- 18,000,000
- 16,000,000
- 14,000,000
- 12,000,000
- 10,000,000
- 8,000,000
- 6,000,000
- 4,000,000
- 2,000,000

IVDU:
- 100,000
- 90,000
- 80,000
- 70,000
- 60,000
- 50,000
- 40,000
- 30,000
- 20,000
- 10,000

UDIV under substitution

Syringes
### Indicators of infection in IVDUs from 1988 to 2002: stated prevalence of HIV and HCV

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IREP</td>
<td>40%</td>
<td>34%</td>
<td>20%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CESES</td>
<td>14%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DREES</td>
<td>23%</td>
<td>14%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PES</td>
<td>23%</td>
<td>19%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0FDT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10%</td>
</tr>
<tr>
<td>HCV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IREP</td>
<td>47%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CESES</td>
<td>60%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DREES</td>
<td>66%</td>
<td></td>
<td></td>
<td></td>
<td>63%</td>
<td></td>
</tr>
<tr>
<td>PES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>58%</td>
<td></td>
</tr>
<tr>
<td>AIDES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>53%</td>
</tr>
<tr>
<td>COQUELICOT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>51%</td>
</tr>
</tbody>
</table>

Emmanuelli J et al. BEH 2003
Comments

- HCV prevalence = HCV incidence x duration of the illness (>10 years)
- => Prevalence reflects:
  - long-term contamination and therefore ancient practices
  - period prior to the rise of the risk-reduction policy

- Prevalence is not a sensitive indicator of the course of the epidemic
- Incidence is a more sensitive indicator of the course of the epidemic
Incidence and risk factors of HCV and HIV infections in a prospective cohort of IVDU in the North and East of France*

Between March 1999 and July 2001, we conducted, in closed partnership with InVS, a prospective cohort study of antibodies to HCV and HIV among IDUs negative for both viruses recruited in the North and East of France

*Lucidarme D, Bruandet A, Ilef D et al. Epidemiology and Infection 2004
Patients and methods

The persons eligible were drug user attendees of 6 care centers in Northern and Eastern France:

- who had injected drugs at least once in their lifetime
- whose HCV serology was presumed to be negative

A blood sample for HCV and HIV tests was taken and a standard questionnaire on their drug habits and injecting practices was administered from all the participants at inclusion and at the end of the follow-up one year later.
Results

Of the 231 HCV-seronegative IDUs enrolled in the study, 3 (2%) died and 63 (27%) did not undergo a final serum test and were excluded from the analysis. 165 participants (71.4%) underwent a final HCV serum test. Among the 165 enrollees, 16 seroconverted for HCV during follow-up. No HIV seroconversion was detected. The crude incidence density rate for HCV infection is therefore 9.0 PY (95%CI: 4.57-13.4).
Incidence of HCV infection according to maintenance therapy

- Méthadone (n=57) - 5.3%
- Buprénorphine (n=77) - 10.4%
- No maintenance therapy (n=31) - 16.1%

P = NS
The incidence of HCV infection remains rather high. The still high proportion of sharing of injection and preparation equipment and continuance of regular injecting practices, perhaps favored by the use of cocaine and the risky nature of occasional and unplanned injections are among the most contributing factors. Assuming that 40 000 active IVDUs are HCV negative we could speculate that 2 700-4 400 IVDUs are contaminated every year in France.
Is HCV contamination of intravenous drug users really unavoidable?
Prevalence of HCV markers in relation to the duration of intravenous drug use

- France 1991
- France 2001
What remains to be done?

1- Prevent syringe use particularly among the youngest drug users
2- Continue the efforts of improvement of the accessibility of injection equipment aimed at preventing sharing and re-use behavior
3- Continue substitution policy but take into account its shortcomings
4- Reinforce screening of HCV infection in IVDUs particularly among those with poor veins and those who had never been tested
5- Reinforce accessibility of IVDUs to treatment
Conclusion

We may conclude that the risk-reduction policy has had a significant but markedly insufficient impact on the hepatitis C epidemic in the drug-user population.

Much remains to be done in order to inflect the prevalence curve of the infection by 2011.
Conclusion

Prevalence of HCV in relation to the duration of IV drug use
Thank you